ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) issued its earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12, Zacks reports.
ProMIS Neurosciences Stock Performance
PMN traded up $0.04 during trading on Tuesday, hitting $0.73. The stock had a trading volume of 73,038 shares, compared to its average volume of 70,651. The stock has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.96. The company has a market capitalization of $23.93 million, a PE ratio of -7.32 and a beta of 0.58. ProMIS Neurosciences has a twelve month low of $0.62 and a twelve month high of $2.61.
Analyst Ratings Changes
Separately, Guggenheim reissued a “buy” rating and set a $6.00 target price on shares of ProMIS Neurosciences in a research report on Tuesday.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Further Reading
- Five stocks we like better than ProMIS Neurosciences
- Stock Market Sectors: What Are They and How Many Are There?
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- How to trade using analyst ratings
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- Compound Interest and Why It Matters When Investing
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
